You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Express Scripts
Merck

Last Updated: February 23, 2024

ELIGARD KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Eligard Kit, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. There are two patents protecting this drug.

This drug has seventy-eight patent family members in twenty-nine countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4th, 1998.

  Try a Trial

Summary for ELIGARD KIT
International Patents:78
US Patents:2
Applicants:1
NDAs:4
Finished Product Suppliers / Packagers: 1
Clinical Trials: 50
Formulation / Manufacturing:see details
DailyMed Link:ELIGARD KIT at DailyMed
Drug patent expirations by year for ELIGARD KIT
Recent Clinical Trials for ELIGARD KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Praful RaviPhase 1/Phase 2
Eli Lilly and CompanyPhase 1/Phase 2
BayerPhase 1/Phase 2

See all ELIGARD KIT clinical trials

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by two US patents.

Patents protecting ELIGARD KIT


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Sustained release polymer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING CANCER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021343-001 Jan 23, 2002 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELIGARD KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021731-001 Dec 14, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021488-001 Feb 13, 2003 ⤷  Try a Trial ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021731-001 Dec 14, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021379-001 Jul 24, 2002 ⤷  Try a Trial ⤷  Try a Trial
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021488-001 Feb 13, 2003 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
Boehringer Ingelheim
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.